CCG-203920 did not affect the improvement of rotarod performance
ON L-Dopa induced by AT-403
To investigate whether CCG-203920 increased the sedative effects along
with the antidyskinetic effect of AT-403, the rotarod performance was
monitored before (baseline, OFF L-Dopa) and after L-Dopa administration
in dyskinetic rats (Arcuri et al. ,
2018; Marti et al. , 2012;
Paolone et al. , 2015) (Fig. 5B).
As expected, the time spent on the rod after L-Dopa administration was
dramatically reduced compared to baseline due to dyskinetic movement
appearance (-76%; df=10 t=4.075). When animals were pretreated with
AT-403, the rotarod performance ON L-Dopa improved and no significant
reduction with respect to baseline condition was observed (Fig. 5B).
CCG-203920 administration did not worsen the motor promoting effect of
AT-403, indicating RGS4 blockade did not potentiate AT-403-induced
sedation.